Angelalign Technology (6699) H1 2025 earnings summary

Executive summary

• Revenue for the six months ended June 30, 2025 rose 33.1% year-over-year to USD161.4 million, driven by strong global market expansion and increased case shipments.

• Net profit surged 583.6% year-over-year to USD14.2 million, with net profit margin improving to 8.8% from 1.7% a year earlier.

• Adjusted net profit reached USD19.5 million, up 84.8% year-over-year, with an adjusted net profit margin of 12.1%.

• Global markets outside mainland China saw rapid growth, with case shipments up 103.5% and revenue from these markets more than doubling.

• The Board declared a special interim dividend of HKD0.46 per share for the period.

Financial highlights

• Gross profit increased 32.9% year-over-year to USD100.6 million; gross margin remained stable at 62.4%.

• EBITDA reached USD23.4 million, and adjusted EBITDA was USD28.2 million for the period.

• Earnings per share (basic and diluted) were USD0.09, up from USD0.02 year-over-year.

• Selling and marketing expenses rose 11.3% to USD53.8 million, but the expense ratio fell to 33.3% due to operational leverage.

• R&D expenses increased to USD12.8 million, reflecting expanded investment.

Outlook and guidance

• Plans to increase investment in R&D, IT, legal, sales, marketing, clinical support, and international infrastructure to support global expansion and compliance.

• Focus on expanding production capacity, digital innovation, brand recognition, and compliance with data security and privacy regulations.

• Management remains confident in long-term industry growth despite macroeconomic and regulatory headwinds.